全文获取类型
收费全文 | 212119篇 |
免费 | 22019篇 |
国内免费 | 13123篇 |
专业分类
耳鼻咽喉 | 2355篇 |
儿科学 | 3012篇 |
妇产科学 | 2009篇 |
基础医学 | 18809篇 |
口腔科学 | 4015篇 |
临床医学 | 24960篇 |
内科学 | 25371篇 |
皮肤病学 | 2391篇 |
神经病学 | 8302篇 |
特种医学 | 8228篇 |
外国民族医学 | 87篇 |
外科学 | 21780篇 |
综合类 | 47070篇 |
一般理论 | 11篇 |
预防医学 | 17996篇 |
眼科学 | 4669篇 |
药学 | 23728篇 |
341篇 | |
中国医学 | 16984篇 |
肿瘤学 | 15143篇 |
出版年
2024年 | 245篇 |
2023年 | 2997篇 |
2022年 | 5895篇 |
2021年 | 9165篇 |
2020年 | 9138篇 |
2019年 | 9442篇 |
2018年 | 5606篇 |
2017年 | 6691篇 |
2016年 | 5441篇 |
2015年 | 9607篇 |
2014年 | 12342篇 |
2013年 | 12851篇 |
2012年 | 18588篇 |
2011年 | 19807篇 |
2010年 | 15239篇 |
2009年 | 12793篇 |
2008年 | 14166篇 |
2007年 | 13680篇 |
2006年 | 12694篇 |
2005年 | 10685篇 |
2004年 | 7742篇 |
2003年 | 7225篇 |
2002年 | 6007篇 |
2001年 | 4506篇 |
2000年 | 3425篇 |
1999年 | 2521篇 |
1998年 | 1425篇 |
1997年 | 1363篇 |
1996年 | 1046篇 |
1995年 | 959篇 |
1994年 | 758篇 |
1993年 | 471篇 |
1992年 | 487篇 |
1991年 | 392篇 |
1990年 | 375篇 |
1989年 | 273篇 |
1988年 | 235篇 |
1987年 | 218篇 |
1986年 | 166篇 |
1985年 | 121篇 |
1984年 | 66篇 |
1983年 | 49篇 |
1982年 | 33篇 |
1981年 | 39篇 |
1980年 | 22篇 |
1979年 | 43篇 |
1977年 | 19篇 |
1976年 | 17篇 |
1974年 | 22篇 |
1973年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
Yan Gao MD Yizhen Liu MD PhD Yafei Wang MD Qingyuan Zhang MD Depei Wu MD Xu Ye MD Jianqiu Wu MD Wei Xu MD Jianfeng Zhou MD Yu Yang MD Hong Cen MD Feng Zhang MD Ying Xiang MD Xiaoqiong Tang MD Kaiyang Ding MD JinYing Lin MD Lei Ma MD Shunqing Wang MD Hao Yu MD Yang Zhao MD Bin Song MD Fangfang Lv MD Huiqiang Huang MD 《Cancer》2023,129(4):551-559
2.
3.
Guo-Chao Zhong Qian Zhu Dong Cai Jie-Jun Hu Xin Dai Jian-Ping Gong Wei-Ping Sun 《International journal of cancer. Journal international du cancer》2023,152(5):835-844
Whether ultra-processed food consumption is associated with the risk of pancreatic cancer has not been determined. We performed a prospective study to fill this gap. A population-based cohort of 98 265 American adults was identified from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Ultra-processed foods were defined by the NOVA classification. Cox regression was used to estimate hazard ratios (HRs) for pancreatic cancer incidence. Subgroup analysis was performed to identify the potential effect modifiers. During a mean follow-up of 8.86 years, 387 pancreatic cancer cases occurred. High consumption of ultra-processed foods was found to be associated with an increased risk of pancreatic cancer (fully adjusted HRquartile 4 vs 1:1.49; 95% confidence interval [CI]: 1.07-2.07; Ptrend = .021) in a linear dose-response manner (Pnonlinearity = .075). Subgroup analysis further found that the positive association of ultra-processed food consumption with the risk of pancreatic cancer was more pronounced in subjects aged <65 years (HRquartile 4 vs 1:2.17; 95% CI: 1.14-4.15) than in those aged ≥65 years (HRquartile 4 vs 1:1.32; 95% CI: 0.88-1.94), though the interaction test failed to achieve the statistical significance (Pinteraction = .061). These findings suggest that reducing ultra-processed food consumption may be beneficial in decreasing pancreatic cancer incidence. 相似文献
4.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
5.
Tie Zhou Shengfei Qin Weidong Xu Shouyan Tang Guanghua Chen Song Li Jianguo Hou Xu Gao Guowei Shi Zhongquan Sun Jie Jin Lijun Chen Weibing Sun Ben Liu Jingen Wang Qinggui Meng Dongwen Wang Zhiquan Hu Dalin He Yong Yang Xishuang Song Cheng Fu Yinhuai Wang Dingwei Ye Wei Zhang 《International journal of cancer. Journal international du cancer》2023,153(4):792-802
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177). 相似文献
6.
Qi Zhang Ye Zhou Lijie Song Weijia Fang Meng Qiu Yanhong Gu Yang Yang Jingdong Zhang Jing Liu Jian Li Ming Lu Tianxiao Gong Xin Wang Yan Li Jun Yang Yingjiang Ye Lin Shen 《International journal of cancer. Journal international du cancer》2023,153(11):1885-1893
Formal multidisciplinary team (MDT) discussions in clinical practice require time and space but have unclear survival benefits for advanced gastrointestinal cancer patients. Our study aimed to investigate the long-term survival of patients with advanced gastrointestinal cancer after MDT decision. From June 2017 to June 2019, continuous MDT discussions on advanced gastrointestinal cancer were conducted in 13 medical centers in China. MDT decisions and actual treatment received by patients were prospectively recorded. The primary endpoint was the difference in overall survival (OS) between patients in the MDT decision implementation and nonimplementation groups. The secondary endpoints included the implementation rate of MDT decisions and subgroup survival analysis. A total of 461 MDT decisions of 455 patients were included in our study. The implementation rate of MDT decisions was 85.7%. Previous treatment had an impact on MDT decision-making. The OS was 24.0 months and 17.0 months in the implementation and nonimplementation groups, respectively. The implementation of MDT decisions significantly reduced the risk of death in multivariate analyses (hazard ratio = 0.518; 95% confidence interval: 0.304-0.884, P = .016). Subgroup analysis showed a significant difference in survival of patients with colorectal cancer, but not in survival of patients with gastric cancer. The rate of secondary MDT discussion was only 5.6% among patients who the MDT decisions were discontinued due to changes in their condition. MDT discussion can prolong the OS of patients with advanced gastrointestinal cancer, especially those with colorectal cancer. Timely scheduling of the subsequent MDT discussion is necessary when the disease condition changes. 相似文献
7.
8.
9.
目的研究老年人群无症状脑小血管病(CSVD)的发生率、影像学特征及其影响因素。方法选取2019年10月至2020年8月在我院老年医学部门诊体检、既往无神经系统疾病病史的老年人共201例, 完善头颅磁共振成像(MRI)检查。采用脑小血管病总负担评分对腔隙灶、脑白质病变、脑微出血及血管周围间隙扩大共4种CSVD影像学特征进行总体评估, 记为0~4分。分析入组人群不同影像学特征分布情况, 并将CSVD总负担评分与其临床情况进行相关性分析。结果本研究中影像学符合CSVD共133例(66.2%)。其中, 腔隙灶44例(21.9%), 中-重度脑室旁白质病变(PVWMH)88例(43.8%), 中-重度深部脑白质病变(DWMH)30例(14.9%), 基底节区血管周围间隙扩大(EPVS)61例(30.3%), 脑微出血(CMB)92例(45.8%)。CSVD总负担评分(OR=1.876, 95%CI:1.045~3.364, χ2=4.441, P=0.035)、PVWMH(OR=2.821, 95%CI:1.517~5.244, χ2=10.752, P=0.001)、DWMH(OR=2.130... 相似文献
10.
Wei Tao Wang Lei Tang Jian Ashaolu Tolulope Joshua Olatunji Opeyemi Joshua 《Metabolic brain disease》2022,37(4):1185-1195
Metabolic Brain Disease - Doxorubicin (DOX) is an effective anticancer drug, however, side effects such as cognitive impairment and cardiotoxicity have limited its clinical use. Juglanin (JUG) is a... 相似文献